Olli Eskola

Olli Eskola

Auto-generated profile, based on publicly available information

Olli Eskola

Radiopharmaceutical Chemistry, Turku PET Centre, University of Turku, Turku, Finland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2018 in Contrast Media & Molecular Imaging
Verified
Journal Article
Open access
PDF file
SHSanna Hellberg
Sanna Hellberg
HLHeidi Liljenbäck
Heidi Liljenbäck
OEOlli Eskola
Olli Eskola
VMVeronique Morisson-Iveson
Veronique Morisson-Iveson
MMMatthew Morrison
Matthew Morrison
Anne RoivainenAnne Roivainen
Anne Roivainen
Intraplaque inflammation plays an important role in the progression of atherosclerosis. The 18 kDa translocator protein (TSPO) expression is upregulated in activated macrophages, representing a potential target to identify inflamed atherosclerotic plaques. We preclinically evaluated18F-GE-180, a novel third-generation TSPO radioligand, in a mouse model of atherosclerosis.Methods. Nine hypercholesterolemic mice deficient in low density lipoprotein receptor and apolipoprotein B48 (LDLR−/−ApoB100/100) and six healthy C57BL/6N mice were injected with 10 MBq of18F-GE-180. Specificity of binding was demonstrated in three LDLR−/−ApoB100/100mice by injection of nonradioactive reference compound of18F-GE-180 before18F-GE-180. Dynamic 30-minute PET was performed followed by contrast-enhanced CT, and the mice were sacrificed at 60 minutes after injection. Tissue samples were obtained for ex vivo biodistribution measurements, and aortas were cut into serial cryosections for digital autoradiography. The presence of macrophages and TSPO was studied by immunohistochemistry. The18F-GE-180 retention in plaque areas with different macrophage densities and lesion-free vessel wall were compared.Results. The LDLR−/−ApoB100/100mice showed large, inflamed plaques in the aorta. Autoradiography revealed significantly higher18F-GE-180 retention in macrophage-rich plaque areas than in noninflamed areas (count densities 150 ± 45 PSL/mm2versus 51 ± 12 PSL/mm2,p<0.001). Prominent retention in the vessel wall without plaque was also observed (220 ± 41 PSL/mm2). Blocking with nonradioactive GE-180 diminished the difference in count densities between macrophage-rich and noninflamed areas in atherosclerotic plaques and lowered the count density in vessel wall without plaque.Conclusion.18F-GE-180 shows specific uptake in macrophage-rich areas of atherosclerotic plaques in mice. However, retention in atherosclerotic lesions does not exceed that in lesion-free vessel wall. The third-generation TSPO radioligand18F-GE-180 did not show improved characteristics for imaging atherosclerotic plaque inflammation compared to previously studied TSPO-targeting tracers.

1 August 2014 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
ASAnniina Snellman
Anniina Snellman
JRJohanna Rokka
Johanna Rokka
FLFrancisco R. Lopez-Picon
Francisco R. Lopez-Picon
OEOlli Eskola
Olli Eskola
MSMario Salmona
Mario Salmona
MHMerja Haaparanta-Solin
Merja Haaparanta-Solin
The purpose of the study was to evaluate the applicability of 18 F-labelled amyloid imaging positron emission tomography (PET) agent [ 18 F]flutemetamol to detect changes in brain beta-amyloid (Aβ) deposition in vivo in APP23, Tg2576 and APPswe-PS1dE9 mouse models of Alzheimer's disease. We expected that the high specific activity of [ 18 F]flutemetamol would make it an attractive small animal Aβ imaging agent. [ 18 F]flutemetamol uptake in the mouse brain was evaluated in vivo at 9 to 22 months of age with an Inveon Multimodality PET/CT camera (Siemens Medical Solutions USA, Knoxville, TN, USA). Retention in the frontal cortex (FC) was evaluated by Logan distribution volume ratios (DVR) and FC/cerebellum (CB) ratios during the late washout phase (50 to 60 min). [ 18 F]flutemetamol binding to Aβ was also evaluated in brain slices by in vitro and ex vivo autoradiography. The amount of Aβ in the brain slices was determined with Thioflavin S and anti-Aβ1−40 immunohistochemistry. In APP23 mice, [ 18 F]flutemetamol retention in the FC increased from 9 to 18 months. In younger mice, DVR and FC/CB50-60 were 0.88 (0.81) and 0.88 (0.89) at 9 months (N = 2), and 0.98 (0.93) at 12 months (N = 1), respectively. In older mice, DVR and FC/CB50-60 were 1.16 (1.15) at 15 months (N = 1), 1.13 (1.16) and 1.35 (1.35) at 18 months (N = 2), and 1.05 (1.31) at 21 months (N = 1). In Tg2576 mice, DVR and FC/CB50-60 showed modest increasing trends but also high variability. In APPswe-PS1dE9 mice, DVR and FC/CB50-60 did not increase with age. Thioflavin S and anti-Aβ1−40 positive Aβ deposits were present in all transgenic mice at 19 to 22 months, and they co-localized with [ 18 F]flutemetamol binding in the brain slices examined with in vitro and ex vivo autoradiography. Increased [ 18 F]flutemetamol retention in the brain was detected in old APP23 mice in vivo. However, the high specific activity of [ 18 F]flutemetamol did not provide a notable advantage in Tg2576 and APPswe-PS1dE9 mice compared to the previously evaluated structural analogue [11C]PIB. For its practical benefits, [ 18 F]flutemetamol imaging with a suitable mouse model like APP23 is an attractive alternative.

18 January 2004 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
OEOlli Eskola
Olli Eskola
TGTove Grönroos
Tove Grönroos
JBJörgen Bergman
Jörgen Bergman
MHMerja Haaparanta
Merja Haaparanta
PMPäivi Marjamäki
Päivi Marjamäki
OSOlof Solin
Olof Solin

30 March 2011 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
OEOlli Eskola
Olli Eskola
TGTove J. Grönroos
Tove J. Grönroos
SFSarita Forsback
Sarita Forsback
JTJohanna Tuomela
Johanna Tuomela
GKGaber Komar
Gaber Komar
OSOlof Solin
Olof Solin

1 September 2018 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
NSNina Savisto
Nina Savisto
JBJörgen Bergman
Jörgen Bergman
JAJussi Aromaa
Jussi Aromaa
SFSarita Forsback
Sarita Forsback
OEOlli Eskola
Olli Eskola
OSOlof Solin
Olof Solin

10 January 2012 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
OEOlli Eskola
Olli Eskola
TGTove J. Grönroos
Tove J. Grönroos
ANAlexandru Naum
Alexandru Naum
PMPäivi Marjamäki
Päivi Marjamäki
SFSarita Forsback
Sarita Forsback
OSOlof Solin
Olof Solin